Randomized studies of SLGT-2 inhibitors and GLP-1 receptor agonists are now followed-up by register studies. And scientists are eagerly presenting real life data these years. This makes professor Anders Green to point out that scientists need to remember openness towards each others' methodological schools. Read the article from Medicinsk Tidsskrift here.
Denmark is a world champion in register studies which has also provided invaluable knowledge in diabetes research. However, legal back-and-forthing can cost us the leading place, experts warn. Read the article at Medicinsk Tidsskrift here.
Professor Anders Green gave an invited presentation on the epidemiological results from the Diabetes Impact Study in connection with the Annual Meeting of the Scandinavian Society for the Study of Diabetes, held the 19th-21st of May in Nyborg (Denmark).
ApEHR has produced a report on behalf on the Danish Multidisciplinary Cancer Groups (DMCG) and the Danish Clinical Registries (RKKP, Regionernes Kliniske Kvalitets-udviklingsprogram) with an analysis of survival over the period 1995-2014 for five major cancer forms in Denmark. The report has now been published and can be found by following the link.
Real life treatment patterns and outcomes in advanced Melanoma patients in Italy and Sweden: The development of a Multi Country Database
This pilot study aims to create an international data platform for real world data on malignant melanoma treatment which can be used in clinical and epidemiological studies to systematically observe and describe patient treatment processes and outcomes. Findings from this pilot study are presented in the poster.
The program UTURN - a life without pills on DR1 (Danish national television), is a part of a research project at Rigshospitalet in Copenhagen, which examines wheter an intensive life style intervention in diabetes patients can reduce patients' need for pharmaceutical treatment for diabetes. Camilla Sorts from ApEHR explains in this program the socio-economical cost of [...]